MNG911
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG881 | — | — | 0.859 |
| 2 | MNG60 | — | — | 0.836 |
| 3 | MNG882 | — | — | 0.817 |
| 4 | MBCProject_5856_T0B_RNA | — | A | 0.814 |
| 5 | s0122234 | — | — | 0.811 |
| 6 | MNG200 | — | — | 0.810 |
| 7 | ERR2208971 | — | — | 0.809 |
| 8 | SRR1313120 | — | A | 0.807 |
| 9 | TCGA-60-2721-01A-01R-0851-07 | — | cohortSQ1 | 0.806 |
| 10 | ERR2208899 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.211 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.133 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.113 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.085 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.081 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.056 | Inavolisib | — uncovered |
| MYOGENESIS | 0.056 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.014 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.011 | Inavolisib | — uncovered |